RxDoctor Payments Data

Yelena Shpigel, MD

Neurology · Meadowbrook, PANPI 1205888377

Payments from drug & device makers

$18,019in general payments, 2019–2025

Across 922 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$2K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$1K
  • Novartis$833
  • plus $10K from 53 others

What the payments were for

  • Speaking & faculty fees$1241%
  • Food & beverage$17,89599%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.84$2,074
AbbVie(2 entities)100$1,570
UCB, Inc.89$1,429
Teva Pharmaceuticals USA, Inc.67$1,041
Biogen50$1,007
Novartis36$833
Amgen35$820
SK Life Science, Inc.53$752
Jazz Pharmaceuticals Inc.28$646
Lilly USA, LLC32$625
Sanofi29$609
AstraZeneca22$525
Amneal Pharmaceuticals LLC26$433
Biohaven Pharmaceutical Holding Company Ltd.18$330
Acorda Therapeutics, Inc15$300
Pfizer12$267
Johnson & Johnson(2 entities)8$266
Bristol Myers Squibb14$262
Acadia Pharmaceuticals Inc12$235
Kyowa Kirin, Inc.10$229
Impel Pharmaceuticals Inc.16$204
Argenx US, Inc.6$202
Eisai Inc.8$188
Harmony Biosciences LLC6$183
TG Therapeutics, Inc.8$179
Biohaven Pharmaceuticals, Inc.8$164
Neurocrine Biosciences, Inc.8$159
Lundbeck LLC7$159
Portola Pharmaceuticals, LLC3$155
Sunovion Pharmaceuticals Inc.11$153
Arbor Pharmaceuticals, Inc.8$144
MDD US Operations, LLC6$143
Genentech USA, Inc.7$137
GE HealthCare6$121
E.r. Squibb & Sons, L.L.C.6$115
Avion Pharmaceuticals5$115
Neurelis, Inc.6$103
Avanir Pharmaceuticals, Inc.5$97
Boston Scientific5$97
Supernus Pharmaceuticals, Inc.5$91
Abbott1$86
Ipsen Biopharmaceuticals, Inc4$83
Sumitomo Pharma America, Inc.5$71
Adamas Pharmaceuticals, Inc.3$65
Upsher-smith Laboratories LLC3$61
Tanabe Pharma America, Inc.3$58
Medtronic(2 entities)3$58
CSL Behring2$57
Merz Pharmaceuticals, LLC2$55
Azurity Pharmaceuticals, Inc.3$54
Currax Pharmaceuticals LLC4$50
Otsuka America Pharmaceutical, Inc.2$34
Banner Life Sciences, LLC1$24
Aprecia Pharmaceuticals, LLC1$20
Bausch Health US, LLC1$18
Corium, LLC1$16
Vertical Pharmaceuticals, LLC1$16
Mallinckrodt Enterprises LLC1$16
Assertio Therapeutics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,019 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$120,785
Medicare patients
397
Services billed
5,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5029$358,400
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$273,647
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$222,188
Kesimpta PenOfatumumab22$209,780
RytaryCarbidopa/Levodopa27$55,709
Emgality PenGalcanezumab-Gnlm45$34,991
BriviactBrivaracetam21$33,292
Nurtec OdtRimegepant Sulfate17$29,192
UbrelvyUbrogepant23$23,305
Aimovig AutoinjectorErenumab-Aooe31$22,580
QuliptaAtogepant17$17,658
NuedextaDextromethorphan Hbr/Quinidine18$15,942
Lacosamide42$9,927
ExelonRivastigmine14$9,446
Memantine Hcl261$6,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$57$222,18822 claims
Amneal Pharmaceuticals LLCRytary$433$55,70927 claims
AbbVieUbrelvy, Qulipta$1,570$40,96240 claims
UCB, Inc.Briviact$1,429$33,29221 claims
PfizerNurtec Odt$267$29,19217 claims
Avanir Pharmaceuticals, Inc.Nuedexta$97$15,94218 claims
NovartisExelon$833$9,44614 claims
Upsher-smith Laboratories LLCTopiramate$61$1,36189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →